EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW

被引：0
|
作者：
Huerfano, C. [1 ]
NinoNino, C. P. [1 ]
Davila, F. [1 ]
Reyes, J. M. [2 ]
Diaz, J. A. [3 ]
机构：
[1] Univ Nacl Colombia, Bogota, Colombia
[2] Pfizer SAS, Bogota, Colombia
[3] Univ Nacl Colombia, Bogota, Colombia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1534
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN201
引用
收藏
页码：A169 / A169
页数：1
相关论文
共 50 条
  • [21] Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
    Badran, Ahmed
    Elshenawy, Mahmoud A.
    Shahin, Amgad
    Aljubran, Ali
    Alzahrani, Ahmed
    Eldali, Abdelmoneim
    Bazarbashi, Shouki
    JCO GLOBAL ONCOLOGY, 2020, 6 : 19 - 26
  • [22] A PHASE IV MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE THERAPY IN CHINESE PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Qin, S.
    Jin, J.
    Guo, J.
    Wang, J.
    Zhou, F.
    Huang, Y.
    Ren, X.
    Ye, D.
    Wang, Q.
    Pan, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 282 - 282
  • [23] Comparison of efficacy, safety,and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
    Wen Cai
    Wen Kong
    Baijun Dong
    Jin Zhang
    Yonghui Chen
    Wei Xue
    Yiran Huang
    Lixin Zhou
    Jiwei Huang
    ChineseJournalofCancer, 2017, 36 (11) : 574 - 582
  • [24] Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
    Cai, Wen
    Kong, Wen
    Dong, Baijun
    Zhang, Jin
    Chen, Yonghui
    Xue, Wei
    Huang, Yiran
    Zhou, Lixin
    Huang, Jiwei
    CHINESE JOURNAL OF CANCER, 2017, 36
  • [25] Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    Flaifel, Abdallah
    Pignon, Jean-Christophe
    Ficial, Miriam
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Barthelemy, Philippe
    Tykodi, Scott S.
    Kocsis, Judit
    Ravaud, Alain
    Rodriguez-Cid, Jeronimo R.
    Pal, Sumanta K.
    Murad, Andre M.
    Ishii, Yuko
    Saggi, Shruti Shally
    McHenry, M. Brent
    Rini, Brian, I
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 78 - 86
  • [26] Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?
    Buti, Sebastiano
    Bersanelli, Melissa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) : 1858 - +
  • [27] ECONOMIC EVALUATION OF SUNITINIB FOR THE FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Novikov, I
    VALUE IN HEALTH, 2012, 15 (04) : A222 - A222
  • [28] Risk of treatment failure after first-line sunitinib therapy in patients with metastatic renal cell carcinoma.
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Hill, Jerrold W.
    Guo, Min Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [29] Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2009, 181 (03): : 1067 - 1067
  • [30] PHARMACOECONOMIC EVALUATION OF SUNITINIB MALATE FOR FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO
    Tenorio, C.
    Vargas, J.
    Rizo-Rios, P.
    Flores-Gil, O.
    Martinez-Fonseca, J.
    Mould-Quevedo, J.
    Davila-Loaiza, G.
    VALUE IN HEALTH, 2009, 12 (03) : A44 - A45
12345